Home CONTACT Bratislava Medical Journal 2023 Bratislava Medical Journal Vol.124, No.11, p.848–855, 2023

Journal info


 


Published Monthly, in English
Founded: 1919
ISSN 0006-9248
(E)ISSN 1336-0345

Impact factor 1.564

 

Aims and Scope
Editorial Info
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Bratislava Medical Journal Vol.124, No.11, p.848–855, 2023

Title: Anticoagulation therapy in hospitalized patients with COVID-19: a meta-analysis of randomized clinical trials
Author: Bruno de Matos AQUINO, Gabriel Tonini PALUDETO, Alcindo CERCI NETO, Paulo Roberto BIGNARDI
Abstract: Thromboembolic events are common in hospitalized patients with COVID-19, suggesting that SARS-CoV-2 infection may be related to a prothrombotic state. Several clinical trials evaluating different anticoagulation strategies were developed. Thus, we proposed conducting a meta-analysis of randomized clinical trials that evaluated the efficacy and safety of therapeutic anticoagulation with heparins in hospitalized patients with COVID-19. We searched PubMed, Cochrane, and Epistemonikos for studies published until December 22, 2022. Nine studies compared prophylactic/intermediate anticoagulation versus therapeutic anticoagulation with heparins were included. Four efficacy and one safety endpoints were analyzed: all-cause mortality, thromboembolic events, pulmonary embolism, need of intensive care unit or non-invasive ventilation, and major bleeding. Compared with prophylactic/intermediate anticoagulation, therapeutic anticoagulation with heparins was not associated with a reduction in all-cause mortality and need of intensive care unit or non-invasive ventilation in hospitalized patients with COVID-19, but showed a reduction in the number of thromboembolic events (RR 0.54, 95% CI 0.41–0.71, I2 = 0 %) and pulmonary embolisms (RR 0.37, 95% CI 0.24–0.57, I2 = 0 %), besides an increase in major bleeding (RR 1.67, 95% CI 1.05–2.64, I2 = 0 %). This meta-analysis did not show a reduction in all-cause mortality in hospitalized patients with COVID-19 who received anticoagulation with heparin at a therapeutic dose compared to those who received a prophylactic/intermediate dose, as well as no significant differences were found in the need of intensive care unit admission or use of non-invasive ventilation. There was, however, a reduction in thromboembolic events, pulmonary embolism, and increased bleeding (Tab. 1, Fig. 5, Ref. 31).
Keywords: COVID-19, anticoagulation, heparins, meta-analysis
Published online: 24-Oct-2023
Year: 2023, Volume: 124, Issue: 11 Page From: 848, Page To: 855
doi:10.4149/BLL_2023_131


download file


© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.